Clinical trials in Meldola – page 6

443 clinical trials in Meldola, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Meldola at a glance

443

clinical trials

Paediatric trials0
Research sites1

Quick filters

443 trials in Meldola

Open in trial search

Non-small cell lung cancer+1

Recruiting

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Breast cancer+2

Recruiting

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Datopotamab Deruxtecan
Sponsor:AstraZeneca AB

Contact Research Centre

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:DB-1303
Sponsor:BioNTech SE

Contact Research Centre

Malignant mast cell neoplasm

Recruiting

Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

InvestigationalNo placebo

Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:BNT326
Sponsor:BioNTech SE

Contact Research Centre

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Pfizer Inc.

Contact Research Centre

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Contact Research Centre

Immune thrombocytopenia

Recruiting

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Desmoid tumour

Recruiting

Study of nirogacestat in adult premenopausal women with desmoid tumors and aggressive fibromatosis to evaluate ovarian function recovery

InvestigationalNo placebo

Study of nirogacestat in adult premenopausal women with desmoid tumors and aggressive fibromatosis to evaluate ovarian function recovery

InvestigationalNo placebo

Italy

Participants:18–64 years
Substances:Nirogacestat Hydrobromide
Sponsor:Springworks Therapeutics Inc.

Contact Research Centre

Acute lymphocytic leukaemia+1

Recruiting

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Ascentage Pharma Group Inc.

Contact Research Centre

Vulval cancer

Recruiting

Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer

Registered drugNo placebo

Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Lenvatinib
Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Contact Research Centre

Adenocarcinoma pancreas+2

Recruiting

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Meldola

What the registry says about research in the country

01 Hematologic Malignancies

Innovative research focusing on blood cancers, including studies of novel therapeutic combinations for acute myeloid leukemia, multiple myeloma, and various lymphomas.

Advanced treatments for diffuse large B-cell lymphoma
Multiple myeloma therapies for transplant-ineligible patients
Novel approaches in myelodysplastic syndrome

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into advanced solid tumors, with particular emphasis on colorectal cancer, non-small cell lung cancer, and breast cancer.

Targeted therapies for metastatic colorectal cancer
Novel combinations for advanced NSCLC
Innovative approaches in metastatic breast cancer

Investigations focus on personalized treatment strategies and novel drug combinations.

03 Genitourinary Cancers

Groundbreaking studies in urological cancers, including research on prostate cancer, urothelial cancer, and renal cell carcinoma.

Advanced treatments for metastatic prostate cancer
Maintenance therapy in urothelial cancer
Immunotherapy approaches in renal cell carcinoma

Research aims to improve survival rates through innovative therapeutic strategies.

Back to Italy All countries